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Abstract: Chronic constipation (CC) remains a common gastrointestinal (GI) disorder that conveys
a substantial healthcare burden. Expert guidelines recommend increasing fiber intake, yet the
clinical evidence to support this needs strengthening for specific fibers. The aim was to evaluate
changes in intestinal transit time and GI symptoms in CC patients who consumed polydextrose.
In a randomized, double-blind, placebo-controlled trial, 128 adults with CC received 8 g or 12 g
polydextrose, or placebo, daily for 4 weeks. Transit time, as primary outcome, was assessed by
radiopaque marker distribution after 2-weeks intervention. Bowel habits, GI symptoms and quality
of life (QOL) were assessed by questionnaire, including the Patient-Assessment of Constipation
(PAC) Symptoms (SYM), and PAC-QOL. Following 2-weeks intervention, no reduction was seen in
transit time in any group and following 2- or 4-weeks intervention, no improvements were seen in
stool frequency or consistency in any group. After 2-weeks intervention with 8 g/day polydextrose
an improvement was seen in the PAC-SYM rectal score (p = 0.041). After 4-weeks intervention both
rectal (p = 0.049) and stool (p = 0.029) scores improved while improvement in the QOL satisfaction
score did not reach significance (p = 0.071). Overall, the results suggest that 2-weeks consumption of
8 or 12 g/day polydextrose does not significantly improve physiological measures of gut function
in CC adults. Longer term consumption may improve clinical measures, but further studies will be
required to substantiate this.
Keywords: constipation; fiber; polydextrose; adult; randomized controlled trial; intestinal transit;
intestinal function; patient-reported outcome
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1. Introduction
Chronic constipation (CC) is a common, heterogeneous, symptom-based GI disorder, with a global
pooled prevalence in adults of 14–16%, though prevalence rates vary considerably depending
on defining criteria [1,2]. In the absence of an organic cause, characteristic symptoms of CC
include infrequent and difficult defecation, feeling of incomplete evacuation, passage of hard
stools, and associated abdominal discomfort and bloating [3–5]; there is considerable overlap with
constipation-predominant irritable bowel syndrome [2,6–8]. The prevalence of constipation is higher
in females than in males and increases with advancing age in both [1,2,9–11]. Pathophysiology of CC
is multifactorial and incompletely understood. Nevertheless, it can be broadly considered an overlap
between GI/colonic dysmotility (manifested as delayed gut or colonic transit) and impairment of rectal
evacuation/pelvic floor dysfunction, which can be due to several identified structural or ‘functional’
obstructive causes [3,12]. The importance of abnormal colorectal sensation [13] and gut dysbiosis [14]
are also gaining increasing recognition.
Only a minority of sufferers with CC seek medical help for their condition [15]. However, due to
its prevalence, CC still conveys a major healthcare burden. In the US in 2010, CC was the fourth
most common GI diagnosis made in patients attending GI clinics, with 3.7 million patient visits
estimated [16]. In the UK, annual expenditure on laxatives exceeds £80 million, with 17.4 million
laxative medications prescribed in 2012 [17]. It is estimated that 10% of community nursing time
is spent on constipation [18]. Perhaps not surprisingly, CC significantly and negatively impacts
health-related quality of life (QOL) [19–21]. While QOL can be improved by reducing symptoms
of constipation [22,23], many patients remain dissatisfied with current treatments [4,24,25], due to
variable efficacy, adverse events, cost, taste and inconvenience.
Management of constipation is challenging. Initial recommendations include lifestyle (e.g.,
increasing fluid intake and levels of exercise) and dietary changes. If these fail, laxatives and other
pharmacological approaches are indicated. In general, first-line management, as endorsed by British,
American, European and other global guidelines, as well as expert commentaries, is to increase fiber
intake through the diet or as a supplement [7,26–30], with 25–35 g/day typically recommended
worldwide [31]. Recent systematic reviews and one meta-analysis, combining thirteen trials and
nine different fibers, indicate that fiber supplementation is indeed of benefit to patients with CC,
with significant increase in stool frequency and softening of stool consistency demonstrated in
comparison to placebo [32–34]. Nevertheless, further clinical studies are needed to better document
the beneficial effect of individual fibers.
Polydextrose (PDX) is a synthetic, randomly bonded polymer, comprising approximately 90%
glucose and 10% sorbitol [35] and is considered as a soluble, non-absorbed and partially fermentable
fiber. Several studies have tested the effect of PDX (8–30 g/day) on bowel function, with variable
results [36,37]. Increases in stool consistency [38–44] and bulk [43,45–48] have most frequently been
reported. Increased stool frequency has also been documented in several studies [40,41,43,48], though
this finding is not consistent [38,42,44,46]. Likewise, PDX has been shown to reduce gut transit time in
some studies [39], but not all [43–45]. This variability in effect may be due to heterogeneity of study
design, populations recruited, and PDX dosage. Indeed, the majority of these studies were performed
in ostensibly healthy subjects [43–45], with only two studies, by Matsuike et al. [40,41], and a subgroup
analysis in a trial by Hengst et al. [39] addressing a target population of constipated adults.
Accordingly, to generate further evidence for the beneficial effect of PDX, the objective of this
study was to evaluate changes in physiological (gut transit time) and clinical (GI symptoms) measures
of gut function in patients with chronic constipation.
Nutrients 2018, 10, 920 3 of 16
2. Materials and Methods
2.1. Study Design
This was a randomized, double-blind, placebo-controlled, parallel study comparing three
study arms with equal allocation ratio. Participants completed a 2-week run-in phase followed by
a 4-week intervention phase. The study followed the principles of the Declaration of Helsinki for
research involving human subjects [49] and Good Clinical Practice requirements. It was approved
by an independent ethical committee (United Committees on Research Involving Human Subjects
(The Netherlands; judgement NL49753.100.14)) and conducted in The Netherlands by Julius Clinical
(Zeist, The Netherlands). Written informed consent was obtained from all participants. The study
was conducted between October 2014 and November 2015 and was registered prior to participant
recruitment at ClinicalTrials.gov as NCT02234518. For reporting, the CONSORT guidelines were
followed (see Supplementary Table S1 for the information checklist).
2.2. Participants
Participants were recruited from an ad hoc database of patients compiled from a network of
approximately 200 general practitioners. Study visits were performed at a single site that housed
the X-ray facility. For inclusion, participants were required to be aged 18–75 year, with BMI
18.5–29.9 kg/m2, and to fulfil the following retrospectively measured criteria: fiber intake ≤ 18 g/day
(determined using the Block Fiber Screener [50], Cleveland Clinic Constipation Score (CCCS) 8–20,
and criteria for constipation with the following definition: symptoms of constipation for ≥3 months,
mean stool type (consistency) of 1–3 measured using the Bristol Stool Form Scale (BSFS) [51],
spontaneous bowel movements 1–3/week, plus at least one of the following: straining on at least
25% of defecations, sensation of incomplete evacuation on at least 25% of defecations, sensation of
anorectal obstruction/blockage on at least 25% of defecations or use of manual maneuvers on at least
25% of defecations. Exclusion criteria included pregnant and breast-feeding women, diagnosed GI
diseases or complications other than chronic constipation (e.g., Crohn’s disease, celiac disease, IBS,
chronic diarrhea), chronic diseases (e.g., cardiovascular, neurological, renal) or medication likely to
affect GI motility or limit normal functions (e.g., reduced mobility, increased fragility), and regular
consumption of fiber supplements.
2.3. Intervention
128 participants were randomized into three groups stratified by gender and females by menstrual
cycle phase. During the 2-week run-in period, participants were instructed to continue with their usual
diet and physical activity but to discontinue use of products containing probiotics or prebiotics and fiber
supplements. Following run-in, participants undertook a 4-week intervention with either polydextrose
(Litesse Ultra, Danisco) at 4 g/serving or 6 g/serving, consumed twice daily, for a total supplementation
of 8 g/day (low dose) and 12 g/day (high dose), respectively, or placebo (maltodextrin), also provided
twice daily. Study products were prepared by Nestlé Product Technology Center (Switzerland) in
a milk powder-based format and provided as individual pre-weighed 24 g portions. Each portion was
to be mixed with 200 mL water at room temperature and consumed immediately. Total carbohydrate
mass content was maintained similar for all groups by varying the maltodextrin added.
Compliance was determined by daily questionnaire recording consumption, with the threshold
determined a priori. Subjects were scored as non-compliant if there was either (1) no consumption
of both servings for more than 2 consecutive days during the first 2 weeks of consumption period,
(2) no consumption of both servings for more than 3 consecutive days during the latter 2 weeks of
the consumption period, or (3) no consumption of both servings of the product on all 3 days prior to
a visit.
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2.4. Outcomes
The primary endpoint was the change in whole GI transit time (WGTT) from baseline (day 0) to the
mid-consumption period time point (day 14), as measured by radio-opaque marker (ROM) technique,
in the subjects who consumed 12 g/day dose polydextrose compared to those who consumed the
placebo. Briefly, participants ingested twelve ROM (CT Transit, Prodimed, France) each day for six
consecutive days followed by an abdominal X-ray on the seventh day. Abdominal X-rays were taken
on day 0 and day 14 (Figure 1) and WGTT was calculated as previously described [52,53].
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For symptom collection, participants were requested to complete a daily bowel diary in which 
they recorded for each bowel movement its completeness, spontaneity and consistency (using the 
BSFS [51]) and the time spent on the toilet, in addition to laxative use in the past 24 h. At baseline 
(day 0), day 14 and day 28 participants also completed a series of self-reported questionnaires that 
were used to evaluate symptoms of constipation and QOL.  
Symptom severity was measured using the Patient Assessment of Constipation (PAC) 
Symptoms (PAC-SYM) questionnaire over a two week recall period, which comprises a twelve-
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was assessed using a visual analogue scale (from 0 = not at all to 10 = all the time). Health-related 
QOL was assessed through the PAC-QOL questionnaire [57], which contains 28 questions (5-point 
Likert scale (0, absent; 4, very severe) grouped into four subdomains (worries and concerns, physical 
discomfort, psychosocial discomfort, and satisfaction). For analysis, the score of each of the five 
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Secondary endpoints were determined a priori and included the assessment of changes in WGTT
in subjects consuming 8 g/day dose polydextrose compared to placebo, changes in regional colonic
transit times (right colon, left colon, and rectosigmoid) and changes in GI symptoms.
For symptom collection, participants were requested to complete a daily bowel diary in which
they recorded for each bowel movement its completeness, spontaneity and consistency (using the
BSFS [51]) and the time spent on the toilet, in addition to laxative use in the past 24 h. At baseline
(day 0), day 14 and day 28 participants also completed a series of self-reported questionnaires that
were used to evaluate symptoms of constipation and QOL.
Symptom severity was measured using the Patient Assessment of Constipation (PAC) Symptoms
(PAC-SYM) questionnaire over a two week recall period, which comprises a twelve-question global
score (with each item a 5-point Likert scale from 0, absent to 4, very severe) that can be subdivided into
three subdomain scores (abdominal, rectal and stool). Global and subdomain scores are calculated as
the mean score of all questions, or the individual subdomain questions, respectively [54]. The global
score has been previously used to categories symptoms as mild (score ≤ 1), moderate (>1–2), severe
(>2–3) and very severe (>3–4) symptoms [23]. A reduction of 0.6 point on the global score has been
suggested as the minimal clinically important difference (MCID) [55]. Symptom severity was also
measured using the CCCS, which is based on an eight-item Likert-like scale (score 0, less severe; 30,
most severe). A score of >8 indicates constipation, and >15 indicates at least moderate severity of
symptoms [56].
Global assessment of efficacy was determined by a global constipation symptom score (GCSS)
that queried the severity of constipation symptoms relative to the start of the study and was assessed
through a single 7-point Likert-like item (markedly worse (−3), somewhat worse (−2), a little bit worse
(−1), no change (0), a little better (1), somewhat better (2), markedly better (3)). Abdominal bloating
was assessed using a visual analogue scale (from 0 = not at all to 10 = all the time). Health-related
QOL was assessed through the PAC-QOL questionnaire [57], which contains 28 questions (5-point
Likert scale (0, absent; 4, very severe) grouped into four subdomains (worries and concerns, physical
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discomfort, psychosocial discomfort, and satisfaction). For analysis, the score of each of the five
positively worded questions (No. 18, 25–28) was reverse coded to be consistent with the remaining
negatively worded questions. A reduction of 0.5 point on the global score has been suggested as the
MCID [57].
Tolerance to the study products was assessed six days after starting the intervention and at
the end of the intervention through an 8-item Likert-like scale (assessing abdominal discomfort and
distension/bloating, flatulence and nausea over the past 24 h and past 6 days).
Adverse events were recorded continuously from the signature date of informed consent to
30 days after the last product intake.
2.5. Sample Size, Randomization and Blinding
Based on published data and using an expected change in WGTT of 20 h, standard deviation of
29.7 h [58] and setting α = 0.05 and β = 0.20, a sample size of 35 subjects per group was calculated.
Subjects were randomly assigned into the three groups with an equal allocation ratio and
incorporating stratification by gender (male/female) and for females by menstrual cycle phase at
screening (mid-follicular/mid-luteal phase and post-menopausal). The randomization sequence was
determined using Medidata Balance (Medidata Solutions, Inc., New York, NY, USA.)
The test products containing placebo or fibre ingredient were indistinguishable with regard to
their sensory properties and were individually coded. Participants, research personnel and those
involved in data handling were blinded until locking of the recorded data in a database.
2.6. Statistics
The primary endpoint, change from baseline of WGTT, was assessed by an analysis of covariance
(ANCOVA) model, correcting for gender and menstrual cycle phase at screening, WGTT at baseline and
treatment group. The secondary endpoints were stool frequency (SBM and CSBM), stool consistency
(BSFS), bloating, GI tolerance, PAC-SYM, PAC-QOL, CCCS and GCSS, which were similarly analysed
by an ANCOVA model correcting for gender and menstrual cycle phase at screening, the symptom
baseline value and treatment group. For stool frequency and consistency, weekly averages were
calculated from all the values accrued in the week preceding the day of interest.
For the safety analysis, all randomized participants who consumed at least one dose of study
product were included. All other analyses were performed using the intention-to-treat population and
tests were two-sided with p < 0.05 considered statistically significant. Statistical tests were performed
using SAS (version 9.2; SAS Institute, Inc., Cary, NC, USA.)
3. Results
3.1. Participant Recruitment and Study Flow
The study was conducted between October 2014 and November 2015. Of the 144 individuals who
gave informed consent and were screened, 128 were enrolled and randomized into the three treatment
groups (polydextrose 8 and 12 g/day, and placebo). Nine subjects dropped out prior to receiving a test
product and were thus excluded from the analysis. Of those, eight withdrew with an explanation
(i.e., adverse event (1), incomplete ROM intake (3), conflict with visit schedule (2), personal reason
(1), and withdrawal of consent (1)) and one withdrew without an explanation. The remaining 119
who received test products were all included in the intention-to-treat analysis (Figure 2). Of the total
randomized, 109 participants (85%) completed the first two weeks of intervention and 103 participants
(80%) completed the planned four-week intervention. Baseline demographic and clinical characteristics
are provided in Table 1.
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Table 1. Baseline population characteristics (ITT population).
Placebo (n = 39) Polydextrose 8 g/day (n = 40) Polydextrose 12 g/day (n = 40)
Age (years), median (range, SD) 30.9 (19–71, 16.0) 29.2 (19–72, 15.7) 46.8 (19–64, 15.1)
Female, n (%) 36 (92.3) 38 (95.0) 37 (92.5)
BMI (kg/m2), mean (S ) 23.9 (3.3) 23.6 (2.9) 23.7 (2.8)
Fiber intake, g/day (SD) 5 3 (2.4) 15.2 (2.3) 14. (2.5)
CCCS, mean (SD) 12.8 ( .3) 13.6 (2.6) 12.4 (2.7)
SBM (n/week), mean (SD) 5.4 (3.0) 4.9 (3.9) 6.3 (4.4)
BSFS, mean (SD) 2.8 (1.1) 2.8 (1.1) 3.0 (1.2)
Bloating, mean (SD) 5.5 (2.4) 6.4 (2.3) 6.0 (2.2)
PAC-SYM (global), mean (SD) 1.7 (0.6) 2.0 (0.7) * 1.6 (0.5)
PAC-QOL (global), mean (SD) 1.4 (0.5) 1.7 (0.6) * 1.3 (0.6)
( r ), a (SD) ( ) 62 (41) 51 (34)
BMI, body mass index; CCCS, Cleveland Clinic constipation s re; SBM, spontaneous bowel movements per week;
BSFS, Bristol stool form scale (weekly mean); PAC-SYM/QOL, patient assessment of constipation-symptoms/quality
of life; WGTT, whole gut transit time; SD, standard deviation. * p < 0.05 for comparison vs. placebo.
3.2. Primary Endpoint
Baseline WGTT values were not different between treatment groups (Table 1). Following two
weeks intervention the 12 g/day dose treatment group did not experience a statistically significant
change in WGTT from baseline compared to placebo (mean difference 11.8, 95% CI−1.3, 24.9, p = 0.077)
(Figure 3 and Table 2).
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Table 2. Whole gut transit time, regional colon transit time, stool frequency and stool consistency
changes from baseline (ITT population).
Placebo oly extrose 8 g/ ay Polydextrose 12 g/day Change from Baseline. Polydextrose12 g/day vs. PLACEBO (ANCOVA Model)
n Mean± SD n Mean± SD n Mean± SD Mean Difference (95% CI) p-Value
Change in WGTT (h)
35 −9.4 ± 27.0 35 −0.9 ± 32.8 35 6.8 ± 26.1 11.8 (−1.3, 24.9) 0.08
Change in Regional CTT (h)
Right colon 35 −4.4 ± 17.1 35 0.5 ± 13.7 35 −1.3 ± 11.6 0.5 (−5.2, 6.2) 0.86
Left colon 35 −1.6 ± 12.8 35 0.4 ± 18.5 35 9.4 ± 16.1 9.3 (2.2, 16.5) 0.01 *
Rectosigmoid 35 −2.7 ± 16.5 35 −1.7 ± 18.7 35 −0.7 ± 14.0 −0.7 (−7.0, 5.6) 0.83
Change in Stool Frequency (Number Per Week)
SBM, 14 days 36 0.6 ± 2.9 35 1.3 ± 3.3 36 0.7 ± 3.3 0.2 ( 1.2, 1.7) 0.77
SBM, 28 days 36 0.1 ± 2.7 34 0.8 ± 2.6 34 −0.6 ± 3.3 0.4 ( 1.6, 0.8) 0.52
CSBM, 14 days 36 1.4 ± 2.6 35 1.1 ± 2.1 36 0.1 ± 2.1 −1.0 (−2.1, 0.0) 0.06
CSBM, 28 days 36 0.6 ± 2.1 34 1.0 ± 2.0 34 −0.2 ± 2.3 −0.5 (−1.5, 0.5) 0.29
Change in Stool Consistency
BSFS, 14 days 36 0.3 ± 1.4 34 0.2 ± 1.2 36 0.3 ± 1.1 0.2 (−0.3, 0.7) 0.51
BSFS, 28 days 36 0.1 ± 1.2 34 0.3 ± 1.1 34 0.3 ± 1.2 0.4 (−0.1, 0.8) 0.14
SBM, spontaneous bowel movements; CSBM, complete SBM; BSFS, Bristol stool form scale (1 = separate hard lumps,
7 = entirely liquid); SD, standard deviation; CI, confidence interval. * p < 0.05.
3.3. Secondary Endpoints
Analysis of the 8 g/day dose treatment group revealed no significant change in WGTT compared
to placebo (Table 2; mean difference 6.7, 95% CI −6.3, 19.6, p = 0.309). In all groups a restricted number
of subjects had very short WGTT. Exclusion of those subjects did not change the observed outcome
effect on WGTT of either 8 g/day or 12 g/day polydextrose (data not shown).
Regional colon transit times suggested that the change seen in WGTT with the 12 g/day
dose polydextrose compared to the placebo was accounted for by the left colon segment (Table 2;
mean difference 9.3, 95% CI 2.2–16.5, p = 0.01). No difference in the left colon transit was seen in
the 8 g/day dose polydextrose group compared to placebo (mean difference 1.7, 95%CI −5.4–8.8,
p = 0.633). In addition, no differences were seen between the treatment groups in either the right colon
or rectosigmoid regions.
Changes in the frequency of spontaneous bowel movements (SBM) (based on data collected
during the week leading up to the study site visit) were similar between groups after both 14 days and
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28 days of intervention (Table 2). When the frequency of complete spontaneous bowel movements
(CSBM) was assessed the 12 g/day dose polydextrose group had a trend to reduced CSBM after
14 days intervention compared to the placebo group (Table 2). This trend was not maintained after
28 days of intervention and was not observed with the 8 g/day dose polydextrose group at either time
point (data not shown). No differences between groups were seen in stool consistency at either time
point (Table 2 and data not shown).
By sensitivity analysis, when the full data set was used (i.e., using all data collected between
visits), an improvement in SBM stool frequency was seen between the 8 g/day dose group and the
placebo (mean difference 1.1, 95% CI 0.1–2.2, p = 0.030). No differences were seen with the 12 g/day
dose group. Additionally, with the full data set, no differences were seen between groups in stool
consistency at either time point (data not shown).
3.4. Patient-Reported Symptoms
The mean PAC-SYM global scores at baseline were 1.7 (SD 0.6), 2.0 (SD 0.7) and 1.6 (SD 0.5)
for the placebo, 8 g/day dose polydextrose and 12 g/day dose polydextrose groups, respectively,
with significant differences seen between the groups for the global score (8 g/day polydextrose
vs. placebo, p = 0.018) and for the abdominal subdomain score (8 g/day polydextrose vs. placebo,
p = 0.039). Following two weeks intervention, the change from baseline of the global score in the
8 g/day dose polydextrose group compared to the placebo showed a numerical trend towards
improvement, which after 4-weeks intervention was significantly different (Table 3). The 12 g/day
dose group did not show this improvement.
Table 3. PAC-SYM change from baseline differences (ITT population).
Placebo Polydextrose 8 g/day Polydextrose 12 g/day
n Mean± SD n Mean± SD n Mean± SD
Change in Global Score
14 days 36 −0.2 ± 0.6 35 −0.5 ± 0.7 * 36 −0.2 ± 0.6
28 days 36 −0.2 ± 0.5 34 −0.7 ± 0.6 ** 34 −0.4 ± 0.8
Change in Abdominal Score
14 days 36 −0.3 ± 0.7 35 −0.6 ± 0.8 36 −0.2 ± 0.7
28 days 36 −0.3 ± 0.8 34 −0.8 ± 0.7 34 −0.3 ± 0.9
Change in Rectal Score
14 days 36 0.1 ± 0.6 35 −0.4 ± 0.8 ** 36 −0.2 ± 0.7 *
28 days 36 −0.1 ± 0.4 34 −0.5 ± 0.7 ** 34 −0.3 ± 0.8 *
Change in Stool Score
14 days 36 −0.2 ± 0.8 35 −0.6 ± 1.0 36 −0.3 ± 0.8
28 days 36 −0.2 ± 0.8 34 −0.8 ± 0.9 ** 34 −0.4 ± 1.0
PAC-SYM, patient assessment of constipation-symptoms; SD, standard deviation. * p < 0.1, ** p < 0.05 for comparison
vs. placebo and are derived from the ANCOVA modelling.
Within the rectal subdomain, the 8 g/day dose group had a significant improvement compared
to placebo at both 2- and 4-weeks treatment. In the 12 g/day dose group a difference was also seen
but remained a trend at 14 days (p = 0.053) and 28 days (p = 0.082). An improvement in the stool
subdomain score was seen after 4-weeks intervention with 8 g/day dose polydextrose compared to
the placebo. No differences were seen for either group in the abdominal subscore.
Assessment of symptoms with the CCCS questionnaire did not reveal any change from baseline
of the total score in any group (data not shown).
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Finally, non-statistically significant improvements were detected after 4-weeks intervention with
the 8 g/day dose polydextrose compared to the placebo in bloating, global and satisfaction subdomain
QOL scores and when the overall severity of symptoms was queried with the GCSS (Table 4).
Whether relationships exist between WGTT and patient-reported outcomes was also assessed.
As shown in Figure 4 no relationship was found between WGTT and either the global score of
PAC-SYM or PAC-QOL at either baseline or following 2-weeks intervention.
Table 4. Quality of life and symptom changes from baseline after 4-weeks intervention with polydextrose.
Placebo Polydextrose8 g/day
Polydextrose
12 g/day
n Mean± SD n Mean± SD n Mean± SD
Change in PAC-QOL Global Score
28 days 36 −0.1 ± 0.5 34 −0.4 ± 0.6 * 34 −0.3 ± 0.7
Change in PAC-QOL Satisfaction Score
28 days 36 −0.1 ± 0.9 34 −0.6 ± 0.9 * 34 −0.3 ± 1.2
Change in Bloating Score
28 days 33 0.2 ± 1.9 32 −1.0 ± 2.4 * 33 −0.6 ± 3.1
Change in GCSS
28 days 36 0.2 ± 1.7 33 0.9 ± 1.8 * 33 0.5 ± 1.9
PAC-QOL, patient assessment of constipation-quality of life; GCSS, global constipation symptom score; SD, standard
deviation. * p < 0.1 for comparison vs. placebo and are derived from the ANCOVA modelling.
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3.5. Adverse Events
Product tolerance was assessed by questionnaire after six and 28 days of intervention. No changes
from baseline were seen in any group (data not shown).
No association was seen between any treatment group and the occurrence of adverse events
(Table 5) nor between the treatment group and the study product (p = 0.291, Fisher’s exact test).
Table 5. Adverse events reported by study participants.
Placebo Polydextrose 8 g/day Polydextrose 12 g/day
p-ValueSubjects, n
(% Group) Events, n
Subjects, n
(% Group) Events, n
Subjects, n
(% Group) Events, n
Any AE/SAE 24 (61.5%) 69 29 (72.5%) 71 30 (75.0%) 81 0.39
Abdominal discomfort 0 (0%) 0 1 (2.5%) 1 1 (2.5%) 1 1.00
Abdominal distension 3 (7.7%) 4 6 (15%) 6 3 (7.5%) 3 0.32
Abdominal pain 9 (23.1%) 18 11 (27.5%) 18 8 (20.0%) 12 0.74
Flatulence 0 (0%) 0 1 (2.5%) 1 0 (0%) 0 1.00
Nausea 2 (5.1%) 2 3 (7.5%) 3 3 (7.5%) 4 1.00
The number of subjects reporting at least one adverse event (AE) or serious adverse event (SAE) and the total
number of events per treatment group. Significance was assessed with the Fisher’s exact test.
4. Discussion
The positive impact that consumption of polydextrose has been reported to have on bowel
function [36,37] led us to hypothesize that 8–12 g/day of polydextrose would lead to a reduction
in WGTT and improve symptoms of constipation in adults. The lower dose of 8 g/day was chosen
based on doses (7–8 g/day) reported at the time to have an impact on bowel function in constipated
participants [39–41]. While both lower (4 g/day) and higher (12 g/day) doses were also reported
to have an impact on bowel function in healthy subjects [48], a single higher dose of 12 g/day was
tested here in the context of chronic constipation. The results of this study, however, do not satisfy
the primary objective as no statistically significant change in WGTT was found between those who
consumed 12 g/day polydextrose and those who consumed placebo for 2-weeks. Indeed, rather than
a reduction in WGTT, the tendency of the 12 g/day dose intervention was to lengthen the WGTT.
Secondary outcome analyses suggested that this lengthening was accounted for by the left colon,
and although there was no change in the number of SBMs, it may also have led to a reduction in the
number of CSBMs. The frequency of CSBM has been suggested to be a better outcome measure than
SBM, given that it reflects the subjective completeness of a defecation event. While transit time was
not measured at the end of the 28 day intervention period, this change in CSBM relative to the placebo
was no longer detected at this time. In this study, the lower dose of polydextrose (8 g/day) also did
not show a significant change in WGTT or a change in stool frequency or consistency.
A major challenge when studying chronic constipation is the inter-individual heterogeneity in
what can be considered as “normal” for stool frequency, consistency and the range of accompanying
symptoms. Added to this is the challenge that, between individuals, symptoms may be interpreted
differently, and their most bothersome symptom or feature can differ largely. Given the inconsistencies
of effects reported with polydextrose in the published literature on stool frequency, stool consistency
and intestinal transit (endpoints that may be considered as key diagnostic criteria for constipation),
we thought it important to assess symptoms and QOL as patient-reported outcomes. Using a selection
of these assessment instruments, the only significant change seen that also met the MCID change
criterion [55] was the PAC-SYM stool subscore after 4-weeks intervention of the low dose of
polydextrose (8 g/day). The absence of a significant increase in GCSS is consistent with a general lack
of a significant clinical effect for polydextrose under these conditions.
That this study was unsuccessful may feasibly be due to subject heterogeneity in the most
bothersome symptom. We used modified Rome III diagnostic criteria for chronic functional
constipation as inclusion conditions, and to limit the severity to those with mild to moderate
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constipation a CCCS score of 8–20 was set, as used elsewhere [59–61]. At baseline, the groups were
well balanced, although compared to the placebo group, the 12 g/day dose polydextrose group had
a slightly higher, albeit statistically non-significant, age (median 47 year vs. placebo 31 year, p = 0.11)
and slightly lower daily intake of fiber (14.2 vs. placebo 15.3 g/day, p = 0.052). Nevertheless following
the run-in period during which daily bowel diary records were kept, many subjects reported higher
stool frequency (median stool frequency (4.0–5.0)) than the inclusion criterion of 1–3 movements per
week. The corresponding stool consistency values remained within the inclusion criterion value of
≤3, although given the variability seen, some participants clearly had a score above this (median
stool consistency (2.7–3.2)). The results of a sensitivity analysis of those participants fulfilling the
inclusion criteria for both stool frequency and consistency at baseline were consistent with that of the
full data set for changes in WGTT, stool frequency and stool consistency (data not shown). The failure
to maintain certain elements of the inclusion criteria post-screening is not uncommon in functional GI
disorders and indeed the potential for symptom variability is encompassed within the Rome III criteria.
Clearly, further studies powered to detect changes and relief of patient-reported symptoms will be
needed. Furthermore, while we tested two doses of polydextrose it may be that these were too high.
As a dose of 4 g/day has already been reported to have a positive impact on bowel function in healthy
subjects [48], additional dose range finding studies in constipated individuals may also be beneficial.
The published literature on the impact of polydextrose has primarily focused on healthy adults
and thus even if the subjects in this trial were not constipated we may have expected to see
a positive impact on WGTT, stool frequency or consistency. But the impact in the healthy individual
is not conclusive and in a recent scientific opinion, the European Food Safety Authority ruled
that the evidence was insufficient to demonstrate an impact of polydextrose in the maintenance
of normal defecation [62]. Furthermore, the quantity of evidence in constipated adults is low.
Two non-placebo-controlled studies suggested that polydextrose could improve stool frequency and
consistency after 10 days intervention [40,41]. Meanwhile another study demonstrated that intestinal
transit time decreased with polydextrose [39]. The authors reported that this improvement, and that of
stool consistency, was seen primarily in a constipated subgroup. Unfortunately, the subgroup analysis
was not shown, limiting the strength of conclusion that can be drawn from these data.
The limited positive effects of polydextrose seen in this study and the relative variability in
symptom improvement seen in the published literature, including in healthy subjects, suggest
that polydextrose may not be the ideal fiber to benefit a heterogeneous population suffering from
constipation. Polydextrose has been reported to be slowly fermented in the colon and early reports
suggested that approximately 30–50% of the ingested dose is excreted [45,63]. Incomplete fermentation
should prolong its water binding and stool bulking capacity, thus improving stool consistency
and volume, two properties believed to facilitate defecation [64]. However, a more recent report
estimated that only 10% of the ingested dose of polydextrose was excreted [38]. Such large differences
in the amount excreted support the notion that subject variances in the fermentative capacity of
the colonic microflora exist [37], and that this capacity may determine the beneficial effect of
polydextrose. Therefore, individuals who ferment polydextrose more completely may thus not
benefit from its defecation-improving effect [65]. Constipation has been associated with changes in the
colonic microbiota [66–68] but an association of microbiota to constipation symptom response with
polydextrose has yet to be shown.
This study has several strengths, not least that it queried a comprehensive array of constipation-
related symptoms and quality of life factors using condition-specific instruments and tested two doses
of polydextrose. In addition, the randomized and blinded allocation and use of placebo aimed to
minimize bias in testing our hypothesis.
The study also has several limitations. Baseline values of key constipation symptoms did not
all meet the inclusion criteria that were measured during screening. Re-screening of participants at
baseline and prior to intervention may be a necessary step [69]. Additionally, slow WGTT was not used
as a screening/inclusion criterion, which may have improved subject homogeneity and thus response
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to intervention [69–71]. Further to this, a change in WGTT was only evaluated at 2-weeks whereas
the patient-report outcome effects suggest that at least 4-weeks intervention may be required. Also,
although the intake of dietary fiber was assessed at screening as an inclusion criterion and participants
were instructed to maintain their regular diet during the study, it was not assessed following the
intervention. Finally, we do not see it as a weakness that our study had a majority of female participants.
We did not fix a women:men ratio for the study and although the data we present is mostly in women it
broadly reflects the reported sex differences in prevalence, and therefore actually increases the external
validity to the population we are investigating. However, gender balance may need to be considered as
it has been reported that there may be gender differences in specific symptoms of constipation [9] and
likely also pathophysiology [72,73]. Women represented >90% of the participants, which precluded
a sensitivity analysis to assess if these results are translatable to men.
In conclusion, this is the first randomized clinical trial to test the impact of polydextrose in
chronically constipated adults. Consumption of 8 g/day or 12 g/day polydextrose for 2 weeks did
not improve measures of intestinal transit, stool frequency or stool consistency. However, our results
suggest that future studies in constipated subjects with longer term intervention (i.e., 4 weeks or
longer) and focused on rectal and stool-related symptoms as well as on QOL-related satisfaction may
be more insightful.
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